| Biomarker ID | 1302 |
| PMID | 24394557 |
| Year | 2014 |
| Biomarker | EZH2 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.85 (95% CI: 0.74–0.97) |
| Effect on Pathways | Pathways include: Cell differentiation pathway, MicroRNAs in muscle cell differentiation, PRC2 complex long-term gene silencing through modification of histone tails, Interleukin-2 signaling pathway |
| Experiment | PCa Specific Survival Vs No PCa Specific Survival |
| Type of Biomarker | Prognostic |
| Cohort | 189 patients from Swedish Cohort were selected for analysis. Survival information was available for 185 patients. 22 are alive, 98 died due to prostate cancer and 65 died due to other causes. 144 samples were available for the analysis of this gene |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.018 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | EZH2 |